Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
77.1M
-
Number of holders
-
96
-
Total 13F shares, excl. options
-
43.5M
-
Shares change
-
+4.24M
-
Total reported value, excl. options
-
$551M
-
Value change
-
+$51.9M
-
Number of buys
-
51
-
Number of sells
-
-47
-
Price
-
$12.67
Significant Holders of Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX) as of Q2 2022
117 filings reported holding NRIX - Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2022.
Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX) has 96 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 43.5M shares
of 77.1M outstanding shares and own 56.37% of the company stock.
Largest 10 shareholders include PRICE T ROWE ASSOCIATES INC /MD/ (4.62M shares), BAKER BROS. ADVISORS LP (3.88M shares), BlackRock Inc. (3.36M shares), Redmile Group, LLC (3.01M shares), Deep Track Capital, LP (2.44M shares), WASATCH ADVISORS INC (2.26M shares), STATE STREET CORP (2.12M shares), VANGUARD GROUP INC (2.11M shares), TRV GP III, LLC (1.92M shares), and Bain Capital Life Sciences Investors, LLC (1.82M shares).
This table shows the top 96 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.